Vycor Medical (VYCO) 10-Q 12 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2014	Nov. 10, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'VYCOR MEDICAL INC	'
Entity Central Index Key	'0001424768	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Document Type	'10-Q	'
Document Period End Date	30-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	10,861,053

Consolidated_Balance_Sheets_Un

Consolidated Balance Sheets (Unaudited) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Current Assets	'	'
Cash	$2,447,147	$31,303
Trade accounts receivable, net of allowance for doubtful accounts of $6,152 and $6,474	151,899	212,660
Inventory	261,549	206,926
Prepaid expenses and other current assets	295,676	208,063
Total Current Assets	3,156,271	658,952
Fixed assets, net of accumulated depreciation of $1,010,225 and $830,291	623,006	706,197
Intangible and Other assets:	'	'
Trademarks	251,157	251,157
Patents, net of accumulated amortization of $434,459 and $328,319	358,532	444,095
Website, net of accumulated amortization of $19,309 and $17,228	13,441	1,680
Security deposits	53,169	53,169
Total Intangible and Other assets	676,299	750,101
TOTAL ASSETS	4,455,576	2,115,250
Current Liabilities	'	'
Accounts payable	145,696	254,024
Accrued interest: Related Party	46,542	238,299
Accrued interest: Other	30,783	147,985
Accrued liabilities	352,755	1,776,867
Other current liabilities	67,130	61,576
Derivative liability	28,820	'
Notes payable: Related Party	'	2,373,556
Notes payable: Other	352,997	578,186
TOTAL CURRENT AND TOTAL LIABILITIES	1,024,723	5,430,493
STOCKHOLDERS' EQUITY ( DEFICIENCY)	'	'
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 235,560 and 16.2 issued and outstanding as at September 30, 2014 and December 31, 2013 respectively	24	1
Common Stock, $0.0001 par value, 25,000,000 shares authorized, 10,851,263 and 6,757,225 shares issued and outstanding at September 30, 2014 and December 31, 2013 respectively	1,085	675
Additional Paid-in Capital	23,846,183	13,762,689
Treasury Stock (103,334 shares of Common Stock as of September 30, 2014 and December 31, 2013 respectively, at cost)	-1,033	-1,033
Accumulated Deficit	-20,443,931	-17,032,405
Accumulated Other Comprehensive Income	28,525	-45,170
Total Stockholders' Equity (Deficiency)	3,430,853	-3,315,243
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)	$4,455,576	$2,115,250

Recovered_Sheet1

Consolidated Balance Sheets (unaudited) (Parenthetical) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Consolidated Balance Sheets [Abstract]	'	'
Allowance for doubtful accounts receivable	$6,152	$6,474
Accumulated depreciation	1,010,225	830,291
Accumulated amortization, Patents	434,459	328,319
Accumulated amortization, Website	$19,309	$17,228
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	235,560	16.2
Preferred stock, shares outstanding	235,560	16.2
Common Stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, shares authorized	25,000,000	25,000,000
Common Stock, shares issued	10,851,263	6,757,225
Common Stock, shares outstanding	10,851,263	6,757,225
Treasury Stock, shares	103,334	103,334

Consolidated_Statement_of_Oper

Consolidated Statement of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Statement of Operations [Abstract]	'	'	'	'
Revenue	$334,339	$321,630	$991,001	$788,258
Cost of Goods Sold	47,340	41,806	125,980	99,718
Gross Profit	286,999	279,824	865,021	688,540
Operating expenses:	'	'	'	'
Research and development	6,933	'	59,684	52,635
Depreciation and Amortization	93,860	90,561	286,955	266,106
General and administrative	623,993	673,464	2,652,393	2,063,232
Total Operating expenses	724,786	764,025	2,999,032	2,381,973
Operating loss	-437,787	-484,201	-2,134,011	-1,693,433
Other expense	'	'	'	'
Interest expense - Related Party	-13,706	-34,081	-80,093	-95,859
Interest expense - Other	-11,169	-14,492	-38,844	-42,546
Loss on extinguishment of debt	-682,039	'	-682,039	'
Loss on extension of warrants	-146,488	'	-146,488	'
Change in fair value derivative liability	8,332	'	-261,661	'
Total Other expense	-845,070	-48,573	-1,209,125	-138,405
Net Loss	-1,282,857	-532,774	-3,343,136	-1,831,838
Comprehensive Income (Loss)	'	'	'	'
Foreign Currency Translation Adjustment	-62,273	25,865	-68,390	14,431
Net Comprehensive Loss	($1,345,130)	($506,909)	($3,411,526)	($1,817,407)
Loss Per Share	'	'	'	'
Basic and diluted	($0.12)	($0.08)	($0.33)	($0.29)
Weighted Average Number of Shares Outstanding	10,735,884	6,481,138	10,106,903	6,231,218

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (Unaudited) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash flows from operating activities:	'	'
Net loss	($3,343,136)	($1,831,838)
Adjustments to reconcile net loss to cash used in operating activities:	'	'
Amortization expense	107,833	97,553
Depreciation expense	190,057	188,602
Share based compensation expense	319,051	316,003
Change in fair value of derivative liability	261,661	'
Loss on extinguishment of debt	682,039	'
Loss on extension of warrants	146,488	'
Changes in assets and liabilities:	'	'
Accounts receivable	60,761	-129,920
Inventory	-54,623	36,457
Prepaid expenses	-166,576	27,718
Accounts payable	-108,189	169,283
Accrued interest: Related Party	-206,244	95,859
Accrued interest: Other	-102,715	42,461
Accrued liabilities	3,743	346,094
Other current liabilities	5,554	-12,281
Cash used in operating activities	-2,204,296	-654,009
Cash flows used in investing activities:	'	'
Purchase of fixed assets	-107,648	-88,813
Acquisition of subsidiary	'	-163,201
Website costs	-13,842	'
Patent costs	-20,191	-68,747
Cash used in investing activities	-141,681	-320,761
Cash flows from financing activities:	'	'
Proceeds from issuance of Common Stock	5,000,000	332,832
Proceeds from issuance of Notes Payable: Related Party	'	550,744
Proceeds from issuance of Notes Payable: Other	81,913	87,044
Repayment of Notes Payable: Related Party	-126,519	'
Repayment of Notes Payable: Other	-198,551	-53,035
Cash provided by financing activities	4,756,843	917,585
Effect of exchange rate changes on cash	4,978	-1,692
Net increase (decrease) in cash	2,415,844	-58,877
Cash at beginning of period	31,303	59,821
Cash at end of period	2,447,147	944
Supplemental Disclosures of Cash Flow information:	'	'
Interest paid:	430,208	88
Non-Cash Transactions:	'	'
Common stock issued on conversion of Preferred C shares	'	1,100,000
Acquisition of subsidiary: Deferred consideration payable	'	161,530
Foreign exchange difference on deferred consideration	'	1,671
Net non-cash transaction	'	$163,201

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2014
Basis of Presentation [Abstract]	'
BASIS OF PRESENTATION	'
	1
	BASIS OF PRESENTATION
	The consolidated financial statements of the Company present the financial position, results of operations, and cash flows of Vycor Medical, Inc. and its wholly owned subsidiaries (the “Company”). All significant intercompany accounts and transactions have been eliminated. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive financial statements have been condensed or omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2013 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013.
	The condensed consolidated financial statements for the three and nine months ended September 30, 2014 and 2013, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition and results of operations. The results of operations for the three and nine months ended September 30, 2014 and 2013 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Certain prior period amounts have been reclassified to conform to the current presentation.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended
	Sep. 30, 2014
Significant Accounting Policies [Abstract]	'
SIGNIFICANT ACCOUNTING POLICIES	'
	2
	SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
	Derivative Liability
	The Company accounts for the 34,723 Series A Warrants issued in connection with the Offering (all as defined in Note 5), the holders of which have not waived their anti-dilution rights (as detailed further in Note 5) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expire, and is classified in the balance sheet as a current liability. Any change in fair value of the warrant liability is recognized in the Company’s statement of operations as other income (loss).
	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage. Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. Capitalized software development costs for the nine months ended September 30, 2014 and 2013 were $100,487 and $0, respectively. During the period the Company’s VRT 7.0 program completed the preliminary project stage, following which there was a capitalization of $56,434 of software development costs. Additional costs of $21,463 were capitalized for the Company’s NeuroEyeCoach program (prior to being brought into service in March 2014 with a total capitalized value of $119,106), and $22,590 for a NeuroEyeCoach retail/physician model.
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		September 30,		September 30,
		2014		2013
	Stock options outstanding		5,557		5,557
	Warrants to purchase common stock		5,911,715		1,413,491
	Debentures convertible into common stock		171,138		368,726
	Preferred shares convertible into common stock		1,110,438		239,265
	Total		7,198,848		2,027,039

Notes_Payable

Notes Payable	9 Months Ended
	Sep. 30, 2014
Notes Payable [Abstract]	'
NOTES PAYABLE	'
	3
	NOTES PAYABLE
	Related Party Notes Payable
	As of September 30, 2014 and December 31, 2013 Related Party Notes Payable consists of:
		30-Sep-14	31-Dec-13
	On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment, and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	441,362
	On March 31, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6%. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	175,000
	On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum. These debentures were originally due August 31, 2011 and the due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below	—	400,000
	On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	300,000
	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	300,900
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into series D convertible preferred stock of Vycor, see below.	—	115,550
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $325,744. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	324,225
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $91,519. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. These notes were repaid in January and February 2014.	—	91,519
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $210,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	190,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $20,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014.	—	20,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to David Cantor, in the aggregate amount of $15,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014.	—	15,000
	Total Related Party Notes Payable:	—	$2,373,556
	Other Notes Payable
	As of September 30, 2014 and December 31, 2013 Other Notes Payable consists of:
		30-Sep-14	31-Dec-13
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended to January 2, 2015, subject to certain early repayment provisions.	300,000	300,000
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	98,550
	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in June 2014.	—	42,900
	In the period September to September 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $10,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	10,000
	—
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $3,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. These notes were repaid in February 2014.	—	3,000
	On October 22, 2013 the Company issued a term note for $100,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due November 30, 2013. This note was repaid in January 2014.	100,000
	Insurance policy finance agreements. During the nine months ended September 30, 2014 the Company received proceeds from Insurance policy finance agreements of $81,913 and made repayments of $52,652	52,997	23,736
	Total Other Notes Payable:	$352,997	$578,186
	On August 5, 2014, the Company entered into a series of agreements with Fountainhead, along with certain other related and non-related parties (together, the “Fountainhead Parties”), to exchange all of the parties’ $2,355,587 of debt into Company Series D Convertible Preferred (“Series D”) shares of an equivalent value that are convertible into Company Common Shares at a price of $2.15. The Fountainhead Parties also received a number of warrants equivalent to 75% of the Company Common Shares issuable on conversion of the Series D, exercisable at $3.08 per share for a period of three (3) years from the date of issuance. Under Applicable Accounting Guidance ASC 405 and 470, the exchange is accounted for as an extinguishment of debt. The Company is required to compare the carrying value of the securities being extinguished with the fair value of the securities being issued in exchange. The fair values of the securities issued were determined using a variety of techniques including Black-Scholes at an aggregate of $3,037,626. The securities issued in exchange were recorded on the balance sheet at this aggregate fair value and the difference of $682,039 between fair value of the new securities and the carrying value of the extinguished securities was recognized in the income statement as a loss on extinguishment of debt.

Segment_Reporting_Geographical

Segment Reporting, Geographical Information	9 Months Ended
	Sep. 30, 2014
Segment Reporting, Geographical Information [Abstract]	'
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	'
	4
	SEGMENT REPORTING, GEOGRAPHICAL INFORMATION
	(a) Business segments
	The Company operates in two business segments: Vycor Medical, which focuses on devices for neurosurgery; and NovaVision, which focuses on neuro stimulation therapies and diagnostic devices for the treatment and screening of vision field loss and which includes Sight Science. Set out below are the revenues, gross profits and total assets for each segment.
		Three Months Ended September 30,				Nine months Ended September 30,
		2014		2013		2014		2013
	Revenue:
	Vycor Medical	$	243,841	$	225,823	$	710,743	$	502,847
	NovaVision		90,498		95,807		280,258		285,411
	Total Revenue	$	334,339	$	321,630	$	991,001	$	788,258
	Gross Profit:
	Vycor Medical	$	207,827	$	197,873	$	618,952	$	449,304
	NovaVision		79,172		81,951		246,069		239,236
	Total Gross Profit	$	286,999	$	279,824	$	865,021	$	688,540
	$
		September 30,		December 31,
		2014		2013
	Total Assets:
	Vycor Medical	$	3,236,376	$	799,120
	NovaVision		1,219,200		1,316,130
	Total Assets	$	4,455,576	2,115,250
	(b) Geographic information
	The Company operates in two geographic segments, the United States and Europe. Set out below are the revenues, gross profits and total assets for each segment.
		Three Months Ended September 30,				Nine months Ended September 30,
		2014		2013		2014		2013
	Revenue:
	United States	$	288,063	$	257,123	$	819,699	$	671,430
	Europe		46,276		64,507		171,302		170,828
	Total Revenue	$	334,339	$	321,630	$	991,001	$	788,258
	Gross Profit:
	United States	$	246,755	$	221,541	$	712,572	$	538,869
	Europe		40,244		58,283	152,449		149,671
	Total Gross Profit	$	286,999	$	279,824	$	865,021	$	688,540
	511,108
		September 30,		December 31,
		2014		2013
	Total Assets:
	United States	$	3,993,530	$	1,604,142
	Europe		462,046
	Total Assets	$	4,455,576	$	2,115,250

Equity

Equity	9 Months Ended
	Sep. 30, 2014
Equity [Abstract]	'
EQUITY	'
	5
	EQUITY
	The Offering
	On January 2, January 31, February 28, March 31, and April 25, 2014 the Company completed five separate closings (the “Closings” of an offering (the “Offering”) of Units comprising shares of common stock (“Common Stock”) (collectively, the “Shares” and individually, a “Share”) and Series A and Series B Warrants (collectively, the “Warrants”) (collectively, the “Units”) to accredited investors (the “Investors”) in a private placement. The Closings comprised the sale of an aggregate of $5,000,000 in the Units), which were issued pursuant to five separate Securities Purchase Agreements between the Company and the Investors in each of the four Closings. In the aggregate, the Company issued 2,777,808 shares of Common Stock, Series A Warrants to purchase an aggregate of 1,388,919 shares of Common Stock and Series B Warrants to purchase an aggregate of 1,388,919 shares of Common Stock.
	Each Unit was priced at $1.80 and comprised of one share of Common Stock, a Series A warrant (the “Series A Warrants”) and a series B warrant (the “Series B Warrants”). The Series A Warrants were detachable and were exercisable over a three-year term and were issued with respect to the purchase of a number of shares of Common Stock equal to 50% of the number of Shares purchased by such investor at an exercise price per share of $2.05. The Series B Warrants were detachable and were exercisable over a three-year term and were issued with respect to the purchase of a number of shares of Common Stock equal to 50% of the number of Shares purchased by such investor at an exercise price per share of $3.08. The Warrants are subject to adjustment for stock splits, stock dividends or recapitalizations.
	Also on January 2, 2014, Fountainhead exchanged an aggregate of $1,426,542 of consulting fees owed to it by the Company for the Units issued in the Offering. In the aggregate, the Company issued to Fountainhead 792,523 shares of Common Stock, Series A Warrants to purchase an aggregate of 396,262 shares of Common Stock and Series B Warrants to purchase an aggregate of 396,262 shares of Common Stock.
	Based on the subscription terms applicable to the holders of the Company’s previously-issued Series C Convertible Preferred Stock, such holders were given the option of exchanging their investment in such unconverted Series C Convertible Preferred Stock and the related warrants into the securities which are the subject of the Offering, based on the amount of their investment in the Series C Convertible Preferred Stock and the related warrants. On February 24, 2014, the holders of 15.15 shares of Series C Convertible Preferred Stock (representing an aggregate investment of $757,700) exchanged their Series C Convertible Preferred Stock and related warrants for an aggregate of 420,838 shares of Common Stock, Series A Warrants to purchase an aggregate of 210,419 shares of Common Stock and Series B Warrants to purchase an aggregate of 210,419 shares of Common Stock.
	Under the terms of the Placement Agent agreement with Garden State Securities, Inc. (“GSS”) (see Note 9), the Company issued an aggregate of 402,033 Placement Agent Warrants, on almost identical terms to the Series A Warrants.
	The Series A Warrants and Placement Agent Warrants carried anti-dilution rights (which arose in the event the Company sold securities at a price below $2.05 within one year of the date that the initial Registration Statement has been declared effective by the SEC). Effective May 15, 2014 these anti-dilution rights were waived for all but 34,723 of the Series A Warrants and for all of the Placement Agent Warrants. Accordingly, 34,723 shares of Common Stock are subject to anti-dilution and are recorded as a derivative liability in accordance with the guidance contained in ASC 815-40-15-7D (see Note 2 and Note 7)
	Other Equity Transactions
	During January to September 2014, the Company issued: 6,532 shares of Common Stock (valued at $15,000) to Steven Girgenti, 6,222 shares of Common Stock (valued at $15,000) to Oscar Bronsther and 5,718 shares of Common Stock (valued at $13,750) to Lowell Rush in consideration for services provided to the Board of Directors; and 2,007 shares of Common Stock (valued at $4,688) to Alvaro Pasual-Leone, 4,014 shares of Common Stock (valued at $9,375) to Josef Zihl and 1,944 shares of Common Stock (valued at $4,688) to each of Jason Barton and Jose Romano in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	During January to September 2014, in accordance with the terms the Consulting Agreement, the Company issued 18,988 shares of Common Stock (valued at $45,000) to Fountainhead.
	During January 2014, the Company issued 3,000 and 2,000 shares of Common Stock (valued at $5,400 and $3,600) to Del Mar Consulting Group, LLC and Alex Partners respectively under the terms of their advisory amendment agreements.
	On March 11, 2014 the Company entered into an Amendment Agreement with GSS. Under the Amendment Agreement, the Company agreed to issue 30,000 shares of Common Stock (valued at $66,000) on the date of the Amendment Agreement in respect of the period January to September 2014, rather than 7,500 shares per month under the original agreement.
	During March 2014, in accordance with the terms of an investor relations advisory agreement, the Company issued 2,500 shares of Common Stock (valued at $4,700) to J and M Group, LLC.
	During June 2014, in accordance with the terms of an investor relations advisory agreement, the Company issued 18,000 shares of Common Stock (valued at $43,020) to Hayden IR, LLC.
	In August 2014, Fountainhead entered into an agreement with the Company preventing it from selling any Vycor Shares currently held by Fountainhead below $4.50. In return, the Company agreed to extend the life of certain of Fountainhead’s existing warrants expiring in 2015 to the same 3-year term as the warrants issued under the exchange of Fountainhead debt into Company Preferred Shares (see Note 3). The fair value of the extended terms was determined, using Black-Scholes, and recorded on the balance sheet, and the difference between fair value of the extended terms and of the existing terms of $146,488 was recognized in the income statement as loss on extension of warrants.

ShareBased_Compensation

Share-Based Compensation	9 Months Ended
	Sep. 30, 2014
Share-Based Compensation [Abstract]	'
SHARE-BASED COMPENSATION	'
	6
	SHARE-BASED COMPENSATION
	Stock Option Plan
	The Company adopted the Vycor Medical, Inc Employee, Director, and Consultant Stock Plan (the “Plan”) as of February 13, 2008. The Plan provides for both incentive stock options and nonqualified stock options to be granted to employees, officers, consultants, independent contractors, directors and affiliates of the Company. The board of directors establishes the terms and conditions of all stock option grants, subject to the Plan and applicable provisions of the Internal Revenue Code. Incentive stock options must be granted at an exercise price not less than the fair market value of the common stock on the grant date. The options granted to participants owning more than 10% of the Company’s outstanding voting stock must be granted at an exercise price not less than 110% of the fair market value of the common stock on the grant date. The options expire on the date determined by the board of directors, but may not extend mare than 10 years from the grant date, while incentive stock options granted to participants owning more than 10% of the Company’s outstanding voting stock expire five years from the grant date. The vesting period for employees is generally over three years. The vesting Period for non-employees is determined based on the services being provided. The maximum number of shares of stock which may be delivered under the plan shall automatically increase by a number sufficient to cause the number of shares covered by the plan to equal 10% of the total number of shares of stock then outstanding on a fully diluted basis.
	Under ASC Topic 718, the Company estimates the fair value of option awards on the date of grant using an option pricing model. The grant date fair value is recognized over the option vesting period, the period during which an empoyee is required to provide service in exchange for the award. No compensation cost is recognized for equity instruments for which employees do not render the requisite service. Under these standards, compensation cost for employee cost for employee stock-based awards is based on the estimated grant-date fair value and recognized over the vesting period of the applicable award on a straight-line basis. No employee stock options were granted for the three- and nine-month periods ended September 30, 2014 and 2013.
	Initial grants of options to purchase 500,000 shares were issued under the Plan on February 13, 2008 to each of Kenneth T. Coviello, the Company’s then Chief Executive Officer and then Heather N. Vinas, the Company’s President at an exercise price of $0.135 per share. The options vested 33-1/3% on each of the first, second, and third anniversary of the grant and expire February 12, 2018. Following Heather Vinas’ resignation as President of the Company in May 2010, 166,667 unvested options were cancelled. These options have been fully expensed.
	Stock appreciation rights may be granted either on a stand alone basis or in conjunction with all or part of any other stock options granted under the plan. As of September 30, 2014 there were no awards of any stock appreciation rights.
	The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant.
	The details of the outstanding rights, options and warrants and value of such rights, options and warrants are as follows:
	STOCK WARRANTS:	Number of shares			Weighted average
					exercise price
					per share
	Outstanding at December 31, 2012		1,749,874		$	3.03
	Granted		—			—
	Exercised		(341,941	)		1.49
	Cancelled or expired		(3,334	)		10.5
	Outstanding at December 31, 2013		1,404,599		$	3.39
	Granted		5,226,120			2.61
	Exercised		—			—
	Cancelled or expired		(719,004	)		4.46
	Outstanding at September 30, 2014		5,911,715		$	2.57
	STOCK OPTIONS:	Number of shares			Weighted average
					exercise price
					per share
	Outstanding at December 31, 2012		5,557		$	20.25
	Granted		—			—
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at December 31, 2013		5,557		$	20.25
	Granted		—			—
	Exercised		—			—
	Cancelled or expired		—			—
	Outstanding at September 30, 2014		5,557		$	20.25
	As of September 30, 2014, the weighted-average remaining contractual life of outstanding warrants and options is 2.33 and 3.63 years, respectively.
	Non-Employee Stock Compensation
	During the nine months ended September 30, 2014, the Company issued an aggregate of 6,532 shares of Common Stock (valued at $15,000) to Steven Girgenti, 6,222 shares of Common Stock (valued at $15,000) to Oscar Bronsther and 5,718 shares of Common Stock (valued at $13,750) to Lowell Rush for services rendered to the board of directors. For the nine months ended September 30, 2014, a total of $43,750 was recognized as share-based compensation for the issuance of these shares.
	During nine months ended September 30, 2014 the Company issued an aggregate of 2,007, 1,944 and 1,944 shares of common stock, respectively, valued at $4,688, to each of Alvaro Pascual-Leone, Jason Barton and Jose Romano and 4,014 shares of common stock valued at $9,375 to Josef Zihl for services rendered to the Scientific Advisory Board of NovaVision. For the nine months ended September 30, 2014, an aggregate of $23,438 was recognized as share-based compensation for the issuance of these shares.
	In November 2013, the Company entered into three-month extension amendments to the existing agreements with Del Mar Consulting, Inc. and Alex Partners, LLC under which 33,000 and 27,000 shares of Company Common Stock respectively were issued, valued at $66,000 and $54,000 respectively. The value of these shares was amortized over the period of the agreement, and for the nine months ended September 30, 2014 stock compensation of $78,620 was recognized as share-based compensation in connection with these agreements. Under the extension agreement, the Company has the option to pay all or part of the monthly fees in cash and for January 2014 3,000 shares valued at $5,400 were issued to Del Mar and 2,000 shares valued at $3,600 were issued to Alex Partners.
	On July 2, 2013, the Company entered into an advisory agreement, amended March 11, 2014 with Garden State Securities, Inc. (“GSS”) to provide certain financial advisory services to the Company. Under the terms of the advisory agreement, the Company issued 30,000 restricted shares of Company Common Stock to GSS in March 2014 valued at $66,000, which is being amortized over the six months from January 1, 2014, being the remaining term of the agreement. For the nine months ended September 30, 2014 stock compensation of $66,000 was recognized as share-based compensation in connection with this agreement.
	On January 2, 2014 the Company issued warrants to Dr. Donald O’Rourke to purchase 7,000 shares of Vycor Common Stock at an exercise price of $3.08 per share, exercisable for a period of three years. The fair value of these warrants was estimated at $5,522 using Black-Scholes and the full value was recognized immediately.
	On January 2, 2014 the Company and Fountainhead amended their Consulting Agreement. Under the Amendment, 18,988 shares valued at $45,000 were issued to Fountainhead in respect of fees for the nine months ended September 30, 2014.
	In March 2014, the Company entered into a one-month investor relations advisory agreement with J and M Group, LLC, under which the Company issued 2,500 shares of Common Stock valued at $4,700, which was fully expensed in March 2014.
	In March 2014, the Company entered into an investor relations advisory agreement with Hayden IR, LLC, under which the Company issued 18,000 shares of Common Stock valued at $43,020, which is being amortized over the six months from April to September, 2014. For the nine months ended September 30, 2014 stock compensation of $43,020 was recognized as share-based compensation in connection with this agreement.
	Aggregate stock-based compensation expense charged to operations for stock and warrants granted to the above non-employees for the nine months ended September 30, 2014 was $319,050. As of September 30, 2014, there was $21,510 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.
	Stock-based compensation expenses related to employee options and warrants granted to non-employees are recognized as the stock options and warrants are earned. The stock options or warrants meet the criteria for equity treatment and the fair value of the stock options or warrants granted is estimated at the grant date and the expense is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. The grant date fair value of employee share options and similar instruments is estimated using the Black-Scholes option pricing model on the basis of the fair value of the underlying common stock on the measurement date, using the assumptions noted in the table below. The fair value of the common stock is determined by the then-prevailing share price. Expected volatility is based on the historical volatility of a peer group of publicly traded companies.
	The following assumptions were used in calculations of the Black-Scholes option pricing model for the nine months ended September 30, 2014 and 2013:
		Nine months ended September 30,
		2014			2013
	Risk-free interest rates		0.78%			—
	Expected life		3 years			—
	Expected dividends		0%			—
	Expected volatility		75%			—
	Vycor Common Stock fair value		$2.05			—

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements [Abstract]	'
FAIR VALUE MEASUREMENTS	'
	7
	FAIR VALUE MEASUREMENTS
	The Company has adopted ASC 820 for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period. The adoption of ASC 820 did not have an impact on the Company’s financial position or results of operations.
	Under the terms of the Offering, during the period January 2 to April 25, 2014, in five separate closings, a total of 2,397,631 Series A Warrants and Placement Agent Warrants were issued as part of the Offering, which carried anti-dilution rights. Effective May 15, 2014 these anti-dilution rights were waived for all but 34,723 of the Series A Warrants and for all of the Placement Agent Warrants. The Company accounts for the Series A Warrants in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period.
	The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis (the Series A Warrants described above) as of September 30, 2014 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the liability, and includes situations where there is little, if any, market activity for the liability:
	Description	30-Sep-14		Level 1		Level 2	Level 3
	Warrant Liability	$28,820		$—		$—	$28,820
	The table below provides a reconciliation of the beginning and ending balances for the liabilities measured using fair significant unobservable inputs (Level 3):
	Balance at December 31, 2013		$	—
	Issuance of Series A Warrants and Placement Agent Warrants as part of Offering Units on January 2, January 31, February 24, February 28 and March 31, April 25, 2014			2,103,195
	Change in fair value during period			261,661
	Reduction in liability from waiver of anti-dilution May 15, 2014			(2,336,036	)
	Balance at September 30, 2014		$	28,820
	The fair value of the Series A Warrants and Placement Agent Warrants was determined using a Monte Carlo Simulation. This model requires the input of highly subjective assumptions, including the expected price volatility, which is based on the historical volatility of a peer group of publicly traded companies. Changes in the subjective input assumptions can materially affect the estimate of fair value of the warrants and the Company’s results of operations could be impacted.
	The following assumptions were used in calculations of the Monte Carlo Simulation model for the nine months ended September 30, 2014 and 2013:
	Expected life
	3 years
	—
		Nine months ended September 30,
		2014	2013
	Risk-free interest rates	0.58-0.93%	—
	Expected dividends	0%	—
	Expected volatility	71–97%	—
	Vycor Common Stock fair value	$1.88–$2.70	—

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2014
Commitments and Contingencies [Abstract]	'
COMMITMENTS AND CONTINGENCIES	'
	8
	COMMITMENTS AND CONTINGENCIES
	Lease
	The Company leases approximately 10,000 sq. ft located at 6401 Congress Ave., Suite 140, Boca Raton, FL 33487 from Catexor Limited Partnership for a gross rent of $14,630 plus sales tax per month. The term of the lease is 5 years and 6 months terminating July, 2017. The Company’s subsidiaries in Germany and the UK occupy properties on short term lease agreements. Rent expense for the nine months ended September 30, 2014 and 2013 were $150,300 and $146,014 respectively.
	Potential German tax liability
	In June 2012 the Company's German subsidiary received a preliminary assessment for Magdeburg City trade tax of approximately €75,000 (approximately $94,000). This assessment is for the 2010 fiscal year and relates to the Company's acquisition of the assets of the former NovaVision, Inc. An initial assessment for corporate tax for the same period has been preliminarily reduced to zero. The Company has not accepted this trade tax assessment and is in discussion with the relevant tax authorities with a view to its reduction. The tax authorities have agreed to suspend the assessment pending the outcome of certain court hearings, and the Company has agreed to make limited monthly payments on account. To the extent that this assessment, a higher or a reduced amount, is ultimately confirmed by the tax authorities, the Company believes it has a very strong claim against certain professional advisors which would offset the liability in full. Accordingly, the Company has made no provision for this liability for the nine months ending September 30, 2014, other than recording the monthly payments as an expense.
	Potential Patent Infringement
	The Company was made aware in 2012 that a competitor had been granted a patent for related technology, and appeared to be entering the market with products that infringe the Company’s own issued patent. Following investigation, the Company has taken steps to initiate an invalidation of the competitor’s patent and enforce its patent rights; in March 2014 the Patent Re-examination Board issued an Examination Decision invalidating all the claims of the competitor’s patent. The competitor has appealed but the Company is contesting the appeal and believes it has a strong case. The Company is now preparing for possible enforcement of the Company’s patent against this competitor. The Company has also been made aware that a second competitor has filed a patent application for related technology and also may be producing a product that potentially infringes the Company’s patent. The company has filed comments at the Chinese Patent Office opposing grant of this competitor’s patent application, and will continue to evaluate whether what further additional actions to take in this instance. As a general rule the Company intends to take all necessary action to protect its patent portfolio. As with all patent infringement actions, there is some risk that the accused infringer will not be found to infringe the claims, and an additional risk that the accused infringer will successfully challenge the validity of the asserted claims.

Consulting_and_Other_Agreement

Consulting and Other Agreements	9 Months Ended
	Sep. 30, 2014
Consulting and Other Agreements [Abstract]	'
CONSULTING AND OTHER AGREEMENTS	'
	9
	CONSULTING AND OTHER AGREEMENTS
	The Company has entered into no new consulting or other agreements during the nine months ended September 30, 2014, other than amendments to existing agreements outlined below. The following agreements remained in force during the period:
	Consulting Agreement with Fountainhead
	Effective as of January 2, 2014, the Company and Fountainhead amended their Consulting Agreement to extend the term of the Consulting Agreement to January 2, 2015. As of January 2014, the monthly retainer payable to Fountainhead was reduced to $10,000 per month, payable $5,000 in cash and the remainder payable in Company Common Stock at the end of each quarter until the occurrence of specified milestones.
	Consulting Agreement with Del Mar Consulting Group, Inc and Alex Partners, LLC.
	In November 2013, the Company entered into three-month extension amendments to the existing agreements with Del Mar Consulting, Inc. and Alex Partners, LLC under which 33,000 and 27,000 shares of Company Common Stock respectively were issued, valued at $66,000 and $54,000 respectively. These agreements expired at the end of February 2014.
	Garden State Securites, Inc. (“GSS”) Advisory and Placement Agent Agreements
	On July 2, 2013, the Company entered into two agreements with GSS one to provide certain financial advisory services to the Company (“Advisory Agreement”) and the other to act as placement agent for the Company (“Placement Agent Agreement”).
	Under the terms of the Advisory Agreement, GSS was engaged on a non-exclusive basis to provide financial advisory services to the Company for at least ninety (90) days and thereafter until either party terminates the arrangement. Under the terms of the Advisory Agreement, as amended on March 14, 2014, the Company issued 45,000 restricted shares of Company Common Stock to the broker-dealer, 15,000 of which were issuable on the date of the execution of the Agreement and 30,000 additional shares were issued on March 11, 2014. The Agreement also called for the Company to reimburse certain out-of-pocket expenses.
	Under the terms of the Placement Agent Agreement, the Company engaged GSS as its exclusive placement agent until the later of (i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement. Normal placement agents fees and expense reimbursement were payable.
	Hayden IR, LLC. Investor Relations Agreement
	In March 2014, the Company entered into a twelve (12) month investor relations advisory agreement, as amended (“Hayden Agreements”) in June 2014, with Hayden IR, LLC. Under the terms of Hayden Agreements, Hayden receives $8,500 in cash per month and 36,000 shares of Common Stock; 18,000 issued in June 2014 and 3,000 shares issued monthly from October 2014 of which 9,000 were issued in November 2014.

Related_Party_Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
RELATED PARTY TRANSACTIONS	'
	10
	RELATED PARTY TRANSACTIONS
	Under the terms of the Offering, there were certain agreements with Related Parties:
	(a)
	Debt Amendment and Repayment. Fountainhead and Peter Zachariou agreed to extend the maturity of all of the Company’s debt obligations due to them due to as of August 9, 2013 (aggregating $2,247,037) to January 2, 2017, subject to the earlier repayment of such debt upon the occurrence of certain specified conditions. Fountainhead and Peter Zachariou further released all security interests associated with any of the obligations and agreed to forebear declaring any event of default under the obligations for a period of 24 months following the date of the Initial Closing. During January and February 2014, also under the terms of the Offering, debt obligations arising since August 9, 2013 were repaid as follows: Fountainhead - $91,519; Peter Zachariou - $20,000; David Cantor - $15,000.
	(b)
	Employment of Chief Executive Officer and Employment Agreements. Effective as of January 2, 2014, our board of directors appointed Peter C. Zachariou, our Executive Vice President, to the additional role as the Company’s Chief Executive Officer. Also effective as of the January 2, 2014 the Company entered into separate, but largely identical Employment Agreements with Mr. Zachariou, Adrian Liddell and David Cantor. Mr. Zachariou’s Employment Agreement commences on the Effective Date and terminates six months following the appointment of a successor Chief Executive Officer; Mr. Liddell’s Employment Agreement commences on the Effective Date and terminates upon the appointment of a successor Chief Financial Officer; and Mr. Cantor’s Employment Agreement commences on the Effective Date and terminates upon the appointment of a successor. The aforementioned Employment Agreements provide for annual compensation of $110,000, payment of which is deferred for 12 months from the
	Effective Date and is subject to the achievement of certain enumerated milestone conditions. Each of these Employment Agreements supersede any prior employment agreements or arrangements between the respective parties.
	(c)
	Amendment to Consulting Agreement. Effective as of January 2, 2014, the Company and Fountainhead amended their Consulting Agreement to extend the term of the Consulting Agreement to January 2, 2015. As of January 2014, the monthly retainer payable to Fountainhead was reduced to $10,000 per month, payable $5,000 in cash and the remainder payable in Company Common Stock at the end of each quarter until the occurrence of specified milestones.
	(d)
	Conversion Agreement. Effective as of January 2, 2014, the Company and Fountainhead entered into a Conversion Agreement whereby Fountainhead agreed to convert all amounts accrued as of the date of the Initial Closing into an investment in that amount in the Offering. Pursuant to the terms of this agreement, Fountainhead converted $1,426,542 of accrued consulting fees into the Units.
	During January to September 2014, in accordance with the terms the Consulting Agreement, the Company issued 18,988 shares of Common Stock (valued at $45,000) to Fountainhead.
	During June 2014 related party accrued interest due payments were made to: Fountainhead ($202,683); Peter Zachariou, a director of the Company ($69,198); and David Cantor, a director of the Company ($247).
	On August 5, 2014, the Company entered into a series of agreements with Fountainhead, along with certain other related and non-related parties (together, the “Fountainhead Parties”), to exchange all of the parties’ $2,355,587 of debt into an equivalent amount of Company preferred equity. This equity exchange will result in the Company’s Shareholders’ Equity being increased by $2,355,587, equivalent to the face amount of the exchanged debt. Under the terms of the exchange, the Fountainhead Parties received $2,355,587 of newly-issued Company Series D Convertible Preferred shares (“Series D”) that are convertible into Company Common Shares at a price of $2.15. The Series D carry a cumulative preferred dividend of 7% per annum, payable in cash or Series D at the Company’s option. On the second (2nd) anniversary of the date of issuance of the Series D, the dividend rate is increased to 12% per annum. The Company is able to redeem the Series D at par at any time, at its sole option. The Fountainhead Parties will received a number of warrants equivalent to 75% of the Company Common Shares issuable on conversion of the Series D, exercisable at $3.08 per share for a period of three (3) years from the date of issuance. If the Series D has not then been redeemed or converted within three years from date of issuance, the Fountainhead Parties will receive additional warrants equivalent to 50% of the shares of the Company Common Shares issuable on conversion of the Series D that they then hold, exercisable at the then market price.
	At the same time, in a transaction not related to the aforementioned exchange of securities, Fountainhead entered into an agreement with the Company preventing Fountainhead from selling any Company Common Shares currently held by Fountainhead below $4.50 per share. In return, the Company agreed to extend the life of certain of Fountainhead’s existing warrants expiring in 2015 to the expiration date as the warrants being issued under the exchange.
	During October 2014 related party accrued interest due payments were made to: Fountainhead ($34,269); and Peter Zachariou, a director of the Company ($12,642).
	There were no other related party transactions during the nine months ended September 30, 2014 other than the payment or accrual of fees under the Fountainhead Consulting agreement described in Note 10 of the financial statements.

Subsequent_Events

Subsequent Events	9 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
SUBSEQUENT EVENTS	'
	11.    SUBSEQUENT EVENTS
	The Company evaluated subsequent events through the date the financial statements were issued:
	During October 2014, the Company issued 1,984 shares of Common Stock (valued at $5,000) to Steven Girgenti, in consideration for services provided to the Board of Directors; and 713 and 1,427 shares of Common Stock respectively (valued at $1,563 and $3,125 respectively) to Alvaro Pascual-Leone and Josef Zihl in respect of their roles as members of the NovaVision, Inc. Scientific Advisory Board.
	During October 2014, the Company entered into consulting agreements with JLS Ventures, LLC (“JLS”) and JDR Capital Partners (“JDR”) relating to implementation of the Company’s global Investor Relations and Public Relations Strategy (“IR/PR Strategy”).
	JLS will perform a broad range of investor relations services for an initial term of 12 months. As consideration for the services, the Company issued 100,000 shares of Company Common Stock (valued at $196,000) on execution of the agreement; and will issue an additional 100,000 shares of Company Common Stock on each of December 31, 2014, March 31, 2015 and June 30, 2015 (the “Additional Issuances”). Each of the Additional Issuances will be made at the sole and absolute discretion of the Company, based upon the Company’s reasonable determination that it is satisfied with the performance of JLS under the agreement with respect to the IR/PR Strategy.
	JDR will provide on-going services related to traditional Media and Investor Relations, development of a new media program, institutional relationships and targeted media for a term of 12 months. As consideration for the services, the Company paid JDR $15,000 upon execution of the agreement and will pay JDR additional payments of $15,000 per month. The agreement may be terminated by either party on thirty (30) days notice and the Company shall only be required to make payments under the agreement through the effective date of any termination.
	Pursuant to the IR/PR Strategy Statement, JLS and JDR will seek to (1) improve upon existing communication channels and (2) identify and deliver new channels for communicating with potential investors, the financial community and customers, and (3) build and disseminate the Company’s IR/PR messages.
	During October 2014 accrued interest due payments were made to: Fountainhead ($34,269); and Peter Zachariou, a director of the Company ($12,642).
	In November 2014, the Company issued 9.000 shares of Common Stock (valued at $19,800) to Hayden IR, under the terms of their agreement.

Significant_Accounting_Policie1

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2014
Significant Accounting Policies [Abstract]	'
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company accounts, transactions, and profits have been eliminated in consolidation.
Recent Accounting Pronouncements	'
	Recent Accounting Pronouncements
	From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that such recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
Derivative Liability	'
	Derivative Liability
	The Company accounts for the 34,723 Series A Warrants issued in connection with the Offering (all as defined in Note 5), the holders of which have not waived their anti-dilution rights (as detailed further in Note 5) in accordance with the guidance contained in ASC 815-40-15-7D, whereby under that provision, because they have anti-dilution rights, they do not meet the criteria for equity treatment and must be recorded as a liability. Accordingly, the Company classifies the warrant instrument as a liability at its fair value and adjusts the instrument to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised or until the anti-dilution provisions contained within the warrant agreements expire, and is classified in the balance sheet as a current liability. Any change in fair value of the warrant liability is recognized in the Company’s statement of operations as other income (loss).
Software Development Costs	'
	Software Development Costs
	The authoritative accounting guidance requires software development costs to be capitalized upon completion of the preliminary project stage. Accordingly, direct internal and external costs associated with the development of the features and functionality of the Company’s software, incurred during the application development stage, are capitalized and amortized using the straight-line method of the estimated life of five years once the software has been brought into service. Capitalized software development costs for the nine months ended September 30, 2014 and 2013 were $100,487 and $0, respectively. During the period the Company’s VRT 7.0 program completed the preliminary project stage, following which there was a capitalization of $56,434 of software development costs. Additional costs of $21,463 were capitalized for the Company’s NeuroEyeCoach program (prior to being brought into service in March 2014 with a total capitalized value of $119,106), and $22,590 for a NeuroEyeCoach retail/physician model.
Net Loss Per Share	'
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive.
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share:
		September 30,		September 30,
		2014		2013
	Stock options outstanding		5,557		5,557
	Warrants to purchase common stock		5,911,715		1,413,491
	Debentures convertible into common stock		171,138		368,726
	Preferred shares convertible into common stock		1,110,438		239,265
	Total		7,198,848		2,027,039

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2014
Significant Accounting Policies [Abstract]	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'
		September 30,		September 30,
		2014		2013
	Stock options outstanding		5,557		5,557
	Warrants to purchase common stock		5,911,715		1,413,491
	Debentures convertible into common stock		171,138		368,726
	Preferred shares convertible into common stock		1,110,438		239,265
	Total		7,198,848		2,027,039

Notes_Payable_Tables

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2014
Notes Payable [Abstract]	'
Components of notes payable	'
		30-Sep-14	31-Dec-13
	On December 29, 2009 and February 3, 2010, the Company issued convertible debentures in the amount of $371,362 and $70,000, respectively, payable to Fountainhead Capital Management (“Fountainhead”), the beneficial owner of more than 50% of the Company’s common stock. These debentures accrue interest at a rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $1.88 per share, subject to adjustment, and does not require bifurcation. These debentures were originally due August 31, 2010 and the due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	441,362
	On March 31, 2010 and October 14, 2010, the Company issued convertible debentures payable to Fountainhead in the amount of $85,000 and $90,000, respectively. These debentures accrue interest at a rate of 6%. The Holder is entitled to convert all or any amount of the principal face amount of the debentures then outstanding into shares of common stock of the Company at the conversion price of $2.63 per share, subject to adjustment and does not require bifurcation. The debentures were originally due August 31, 2011, and the due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	175,000
	On October 26, 2010 and November 15, 2010, the Company issued debentures payable to Fountainhead in the amount of $77,500 and $322,500, respectively. These debentures accrue interest at a rate of 6% per annum. These debentures were originally due August 31, 2011 and the due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below	—	400,000
	On November 15, 2010, the Company issued a convertible debenture in the amount of $350,000 payable to Peter Zachariou, a Director of the Company. This debenture accrues interest rate of 6% per annum. The Holder is entitled to convert all or any amount of the principal face amount of the debenture then outstanding into shares of common stock of the Company at the conversion price of $2.85 per share, subject to adjustment and does not require bifurcation. On December 20, 2010, the Company repaid $50,000 of this debenture and removed the convertible rights. The debentures were originally due December 31, 2012 and the due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	300,000
	In the period July to December 2012 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $300,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	300,900
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $115,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into series D convertible preferred stock of Vycor, see below.	—	115,550
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $325,744. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	324,225
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Fountainhead in the aggregate amount of $91,519. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. These notes were repaid in January and February 2014.	—	91,519
	In the period January to September 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $210,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	190,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Peter Zachariou in the aggregate amount of $20,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014.	—	20,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to David Cantor, in the aggregate amount of $15,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in February 2014.	—	15,000
	Total Related Party Notes Payable:	—	$2,373,556
	Other Notes Payable
	As of September 30, 2014 and December 31, 2013 Other Notes Payable consists of:
		30-Sep-14	31-Dec-13
	On March 25, 2011 the Company issued a term note for $300,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due June 25, 2011. In connection with the loan the Company also issued EuroAmerican warrants to purchase 400,000 shares of the Company’s common stock at an exercise price of $4.50 per share for a period of three (3) years. On June 25, 2011 the due date for this note was extended to September 25, 2011 and the Holder was granted the right to convert all or any amount of the principal face amount of the debenture then outstanding and accrued interest into shares of common stock of the Company an adjusted conversion price of $1.80 per share, subject to adjustment and does not require bifurcation. The due date for this note has been extended to January 2, 2015, subject to certain early repayment provisions.	300,000	300,000
	In the period August to December 2012 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $98,550. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	98,550
	In September 2012 the Company issued short term, unsecured notes payable to Osbaldo Trading Limited in the amount of $42,900. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. This note was repaid in June 2014.	—	42,900
	In the period September to September 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $10,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. The due date for this note was extended to January 2, 2017, subject to certain early repayment provisions. On August 5, 2014 the holder exchanged the note into Series D Convertible Preferred Stock of Vycor, see below.	—	10,000
	In the period August 9 to December 2013 the Company issued short term, unsecured notes payable to Craig Kirsch in the aggregate amount of $3,000. The notes accrue interest at a rate of 6% per annum, are due on demand or one year after the issue date and are junior to the secured debentures and Preferred C Stock of the Company. These notes were repaid in February 2014.	—	3,000
	On October 22, 2013 the Company issued a term note for $100,000 to EuroAmerican Investment Corp. (“EuroAmerican”). The term note bears interest at 16% per annum and was due November 30, 2013. This note was repaid in January 2014.	—	100,000
	Insurance policy finance agreements. During the nine months ended September 30, 2014 the Company received proceeds from Insurance policy finance agreements of $81,913 and made repayments of $52,652	52,997	23,736
	Total Other Notes Payable:	$352,997	$578,186

Segment_Reporting_Geographical1

Segment Reporting, Geographical Information (Tables)	9 Months Ended
	Sep. 30, 2014
Segment Reporting, Geographical Information [Abstract]	'
Business segments information	'
		Three Months Ended September 30,					Nine months Ended September 30,
			2014		2013			2014		2013
	Revenue:
	Vycor Medical		$	243,841	$	225,823		$	710,743	$	502,847
	NovaVision			90,498		95,807			280,258		285,411
	Total Revenue		$	334,339	$	321,630		$	991,001	$	788,258
	Gross Profit:
	Vycor Medical		$	207,827	$	197,873		$	618,952	$	449,304
	NovaVision			79,172		81,951			246,069		239,236
	Total Gross Profit		$	286,999	$	279,824		$	865,021	$	688,540
			September 30,		December 31,
			2014		2013
	Total Assets:
	Vycor Medical		$	3,236,376	$	799,120
	NovaVision			1,219,200		1,316,130
	Total Assets		$	4,455,576	$	2,115,250
Summary of geographic information	'
			Three Months Ended September 30,					Nine months Ended September 30,
			2014		2013			2014		2013
	Revenue:
	United States		$	288,063	$	257,123		$	819,699	$	671,430
	Europe			46,276		64,507			171,302		170,828
	Total Revenue		$	334,339	$	321,630		$	991,001	$	788,258
	Gross Profit:
	United States		$	246,755	$	221,541		$	712,572	$	538,869
	Europe			40,244		58,283			152,449		149,671
	Total Gross Profit		$	286,999	$	279,824		$	865,021	$	688,540
			September 30,		December 31,
			2014		2013
	Total Assets:
	United States		$	3,993,530	$	1,604,142
	Europe			462,046		511,108
	Total Assets		$	4,455,576	$	2,115,250

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2014
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]	'
Shedule of the outstanding rights, options and warrants and value of such rights, options and warrants	'
	STOCK WARRANTS:		Number of			Weighted average
			shares			exercise price
						per share
	Outstanding at December 31, 2012			1,749,874		$	3.03
	Granted			—			—
	Exercised			(341,941	)		1.49
	Cancelled or expired			(3,334	)		10.5
	Outstanding at December 31, 2013			1,404,599		$	3.39
	Granted			4,404,401			2.52
	Exercised			—			—
	Cancelled or expired			(582,477	)		4.45
	Outstanding at June 30, 2014			5,226,523		$	2.54
	STOCK OPTIONS:			Number of			Weighted average
				shares			exercise price
							per share
	Outstanding at December 31, 2012			5,557		$	20.25
	Granted			—			—
	Exercised			—			—
	Cancelled or expired			—			—
	Outstanding at December 31, 2013			5,557		$	20.25
	Granted			—			—
	Exercised			—			—
	Cancelled or expired			—			—
	Outstanding at June 30, 2014			5,557		$	20.25
Assumptions used in calculations of the Black-Scholes option pricing model for options and warrants	'
		Nine months ended September 30,
		2014	2013
	Risk-free interest rates	0.58-0.93%	—
	Expected life	3 years	—
	Expected dividends	0%	—
	Expected volatility	71–97%	—
	Vycor Common Stock fair value	$1.88–$2.70	—
Stock options [Member]	'
Share-Based Compensation Arrangement By Share-Based Payment Award [Line Items]	'
Assumptions used in calculations of the Black-Scholes option pricing model for options and warrants	'
		Six months ended June 30,
			2014			2013
	Risk-free interest rates			0.78	%		—
	Expected life			3 years			—
	Expected dividends			0	%		—
	Expected volatility			75	%		—
	Vycor Common Stock fair value		$	2.05			—

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2014
Fair Value Measurements [Abstract]	'
Schedule liabilities measured at fair value on a recurring basis	'
	Description	30-Sep-14		Level 1		Level 2	Level 3
	Warrant Liability	$28,820		$—		$—	$28,820
Schedule of liabilities measured using fair significant unobservable inputs (Level 3)	'
	Balance at December 31, 2013		$	—
	Issuance of Series A Warrants and Placement Agent Warrants as part of Offering Units on January 2, January 31, February 24, February 28 and March 31, April 25, 2014			2,103,195
	Change in fair value during period			261,661
	Reduction in liability from waiver of anti-dilution May 15, 2014			(2,336,036	)
	Balance at September 30, 2014		$	28,820
Schedule of fair value assumptions used in calculation of the Monte Carlo Simulation model	'
		Nine months ended September 30,
		2014	2013
	Risk-free interest rates	0.58-0.93%	—
	Expected life	3 years	—
	Expected dividends	0%	—
	Expected volatility	71–97%	—
	Vycor Common Stock fair value	$1.88–$2.70	—

Significant_Accounting_Policie3

Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	7,198,848	2,027,039
Stock options outstanding [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,557	5,557
Warrants to purchase common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	5,911,715	1,413,491
Debentures convertible into common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	171,138	368,726
Preferred shares convertible into common stock [Member]	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	'	'
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,110,438	239,265

Significant_Accounting_Policie4

Significant Accounting Policies (Details Textual) (USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Significant Accounting Policies (Textual)	'	'
Estimated useful life of software	'5 years	'
Capitalized software development cost	$100,487	$0
Preliminary project stage, software development costs	56,434	'
Capitalized software development cost additions	21,463	'
Total capitalized value	119,106	'
NeuroEyeCoach retail [Member]	'	'
Significant Accounting Policies (Textual)	'	'
Total capitalized value	$22,590	'
Series A Warrants [Member]	'	'
Significant Accounting Policies (Textual)	'	'
Warrants issued in connection with offering	34,723	'

Notes_Payable_Details

Notes Payable (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	$441,362
Convertible debentures issued on March 31, 2010 and October 14, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	175,000
Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	400,000
Convertible debenture issued on November 15, 2010 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	300,000
Short term, unsecured notes payable issued on July to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	300,900
Short term, unsecured notes payable issued on August to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	115,550
Short term, unsecured notes payable issued on January to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	324,225
Short term, unsecured notes payable issued on August 9 to December 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	91,519
Short term, unsecured notes payable issued on Januar to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	190,000
Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	20,000
Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	15,000
Term notes issued on March 25, 2011[Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	300,000	300,000
Short term, unsecured notes payable issued to Craig Kirsch on August to December 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	98,550
Short term, unsecured notes payable issued September 2012 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	42,900
Short term, unsecured notes payable issued to Craig Kirsch on September to September 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	10,000
Unsecured loans issued in August 9 to December 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	3,000
Term notes issued on October 22, 2013 [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	'	100,000
Insurance policy finance agreements [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	52,997	23,736
Other Notes Payable [Member]	'	'
Components of notes payable	'	'
Total Related Party Notes Payable:	$352,997	$578,186

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

9 Months Ended

Sep. 30, 2014

Sep. 30, 2014

Aug. 05, 2014

Feb. 03, 2010

Dec. 29, 2009

Oct. 14, 2010

Mar. 31, 2010

Nov. 15, 2010

Oct. 26, 2010

Nov. 15, 2010

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Mar. 25, 2011

Sep. 30, 2014

Sep. 30, 2012

Sep. 30, 2014

Sep. 30, 2014

Oct. 22, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Fountainhead [Member]

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on December 29, 2009 and February 3, 2010 [Member]

Convertible debentures issued on March 31, 2010 and October 14, 2010 [Member]

Convertible debentures issued on March 31, 2010 and October 14, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Debentures payable issued on October 26, 2010 and November 15, 2010 [Member]

Convertible debenture issued on November 15, 2010 [Member]

Short term, unsecured notes payable issued on July to December 2012 [Member]

Short term, unsecured notes payable issued on August 9 to December 2013 [Member]

Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1

Term notes issued on March 25, 2011[Member]

Short term issued in August to December 2012 [Member]

Short term, unsecured notes payable issued September 2012 [Member]

Insurance policy finance agreements [Member]

Unsecured loans issued in August 9 to December 2013 [Member]

Term notes issued on October 22, 2013 [Member]

Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 1

Short term, unsecured notes payable issued on August 9 to December 2013 [Member] 2

Short term, unsecured notes payable issued to Craig Kirsch on August to December 2012 [Member]

Short term, unsecured notes payable issued on August to December 2012 [Member]

Short term, unsecured notes payable issued to Craig Kirsch on September to September 2013 [Member]

Notes Payable (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Issuance of convertible debentures

'

'

'

$70,000

$371,362

$90,000

$85,000

$322,500

$77,500

$350,000

$300,900

$91,519

$20,000

'

$325,744

$42,900

$81,913

$210,000

$100,000

$115,550

$15,000

$98,550

$3,000

$10,000

Term notes payables

'

'

'

'

'

'

'

'

'

'

'

'

'

300,000

'

'

'

'

'

'

'

'

'

'

Percentage of company's common stock hold by beneficial owner

'

'

'

50.00%

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on debentures

'

'

'

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

6.00%

'

6.00%

6.00%

'

6.00%

16.00%

6.00%

6.00%

6.00%

6.00%

6.00%

Conversion price

'

'

'

$1.88

$1.88

$2.63

$2.63

'

'

$2.85

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Repayment of convertible debt

'

'

'

'

'

'

'

'

'

50,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate on term notes

'

'

'

'

'

'

'

'

'

'

'

'

'

16.00%

'

'

'

'

'

'

'

'

'

'

Number of common stock purchased by issuance of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

400,000

'

'

'

'

'

'

'

'

'

'

Exercise price of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

$1.80

'

'

'

'

'

'

'

'

'

'

Period of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

Debt instrument, maturity date, description

'

'

'

'

'

'

'

'

'

'

'

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'

'

'

'

'Due on demand or one year after the issue date

'

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

'Due on demand or one year after the issue date

Debt instruments, original maturity date

'

'

'

31-Aug-10

31-Aug-10

31-Aug-11

31-Aug-11

31-Aug-11

31-Aug-11

31-Dec-12

'

'

'

25-Jun-11

'

'

'

'

30-Nov-13

'

'

'

'

'

Debt instruments, extended maturity date description

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The due date for this note was extended to January 2, 2017

'

'The due date for this note was extended to January 2, 2017,

Due date was extended to January 2,2017,

Due date was extended to January 2, 2017

Due date was extended to January 2, 2017

Due date was extended to January 2, 2017

Due date was extended to January 2, 2017

Due date was extended to January 2, 2017

Due date was extended to January 2, 2017

Due date was extended to January 2, 2017,

Due date has been extended to January 2, 2017

The due date for this note has been extended to January 2, 2015,

due date was extended to January 2, 2017

Due date has been extended to January 2, 2017

Debt notes repaid description

'

'

'

'

'

'

'

'

'

'

'

'

'This note was repaid in February 2014.

'

'

'This note was repaid in June 2014

'

'

'This note was repaid in January 2014.

'This note was repaid in February 2014.

'

'

'

'

This note was repaid in February 2014.

These notes were repaid in February 2014.

Repayments of insurance policy

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

52,652

'

'

'

'

'

'

'

Debt converted into preferred shares

'

'

2,355,587

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock price per share

'

'

$2.15

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of warrants issued as common stock to debtors

'

'

75

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrant

'

'

$3.08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair value of securities

'

'

'3,037,626

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extinguishment of debt

($682,039)

($682,039)

$682,039

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Segment_Reporting_Geographical2

Segment Reporting, Geographical Information (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenue:	'	'	'	'	'
Total Revenue	$334,339	$321,630	$991,001	$788,258	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	286,999	279,824	865,021	688,540	'
Total Assets:	'	'	'	'	'
Total Assets	4,455,576	'	4,455,576	'	2,115,250
Vycor Medical [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	243,841	225,823	710,743	502,847	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	207,827	197,873	618,952	449,304	'
Total Assets:	'	'	'	'	'
Total Assets	3,236,376	'	3,236,376	'	799,120
NovaVision [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	90,498	95,807	280,258	285,411	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	79,172	81,951	246,069	239,236	'
Total Assets:	'	'	'	'	'
Total Assets	$1,219,200	'	$1,219,200	'	$1,316,130

Segment_Reporting_Geographical3

Segment Reporting, Geographical Information (Details 1) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2013
Revenue:	'	'	'	'	'
Total Revenue	$334,339	$321,630	$991,001	$788,258	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	286,999	279,824	865,021	688,540	'
Total Assets:	'	'	'	'	'
Total Assets	4,455,576	'	4,455,576	'	2,115,250
United States [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	288,063	257,123	819,699	671,430	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	246,755	221,541	712,572	538,869	'
Total Assets:	'	'	'	'	'
Total Assets	3,993,530	'	3,993,530	'	1,604,142
Europe [Member]	'	'	'	'	'
Revenue:	'	'	'	'	'
Total Revenue	46,276	64,507	171,302	170,828	'
Gross Profit:	'	'	'	'	'
Total Gross Profit	40,244	58,283	152,449	149,671	'
Total Assets:	'	'	'	'	'
Total Assets	$462,046	'	$462,046	'	$511,108

Segment_Reporting_Geographical4

Segment Reporting, Geographical Information (Details Textual)	9 Months Ended
	Sep. 30, 2014
	Segment
Segment Reporting, Geographical Information (Textual)	'
Number of business segments	2
Number of geographic segments	2

Equity_Details

Equity (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

2 Months Ended

9 Months Ended

9 Months Ended

1 Months Ended

9 Months Ended

1 Months Ended

Aug. 14, 2007

Sep. 30, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2013

Feb. 24, 2014

Jan. 02, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Aug. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Feb. 24, 2014

Sep. 30, 2014

Jan. 02, 2014

Feb. 24, 2014

Sep. 30, 2014

Sep. 30, 2014

Feb. 24, 2014

Sep. 30, 2014

Jan. 02, 2014

Feb. 24, 2014

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Josef Zihl [Member]

Fountainhead Capital Partners Limited [Member]

Fountainhead Capital Partners Limited [Member]

Lowell Rush [Member]

Securities Offering [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Consulting and Advisory Services [Member]

Common Stock [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series A Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series B Warrants [Member]

Series C Preferred Stock [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Garden State Securities, Inc (GSS)

J and M Group, Llc [Member]

Fountainhead [Member]

Fountainhead Capital Partners Limited [Member]

Fountainhead Capital Partners Limited [Member]

Placement Agent Agreement [Member]

Placement Agent Agreement [Member]

Fountainhead Capital Partners Limited [Member]

Fountainhead Capital Partners Limited [Member]

Equity (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate sale of closing comprised shares, value

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock shares, Shares

'

2,777,808

'

2,777,808

'

420,838

792,523

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

34,723

210,419

1,388,919

396,262

'

'

'

210,419

1,388,919

396,262

'

Shares issued during period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

402,033

34,723

1,130,621

'

'

'

'

Common Stock, par value (in dollars per share)

'

$0.00

'

$0.00

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants exercisable period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'3 years

'

'

'

'

Number of shares of common stock percentage

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

50.00%

'

'

'

'

Warrant exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4.50

'

'

'

'

'

'

'

'

'

$1.80

$2.05

'

'

'

'

'

$3.08

'

'

'

'

Shares of series C convertible preferred stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.15

Aggregate investment amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

757,700

Conversion of stock, shares converted

107

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued value

'

'

'

'

'

'

'

'

15,000

15,000

4,688

4,688

4,688

9,375

'

30,000

5,718

'

'

5,400

3,600

66,000

4,700

45,000

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued shares

'

'

'

'

'

'

'

'

6,532

6,222

2,007

1,944

1,944

4,014

'

12,605

13,750

'

'

3,000

2,000

30,000

2,500

18,988

'

'

'

'

'

'

'

'

'

'

'

'

Shares under the original Agreement

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued consulting fee

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,426,542

'

'

'

'

'

'

'

Issuance Of Series A Warrants And Placement Agent Warrants Shares

'

'

'

2,397,631

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss on extension of warrants

'

($146,488)

'

($146,488)

'

'

'

'

'

'

'

'

'

'

$146,488

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

ShareBased_Compensation_Detail

Share-Based Compensation (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2014	Dec. 31, 2013
Stock Warrants [Member]	'	'
Details of the outstanding rights, options and warrants and value of such rights, options and warrants	'	'
Options Outstanding, Beginning Balance	1,404,599	1,749,874
Number of shares, Granted	5,226,120	'
Number of shares, Exercised	'	-341,941
Number of shares, Cancelled or expired	-719,004	-3,334
Options Outstanding, Ending Balance	5,911,715	1,404,599
Weighted average exercise price per share, Outstanding, Beginning Balance	$3.39	$3.03
Weighted average exercise price per share, Granted	$2.61	'
Weighted average exercise price per share, Exercised	'	$1.49
Weighted average exercise price per share, Cancelled or expired	$4.46	$10.50
Weighted average exercise price per share, Outstanding, Ending balance	$2.57	$3.39
Stock options [Member]	'	'
Details of the outstanding rights, options and warrants and value of such rights, options and warrants	'	'
Options Outstanding, Beginning Balance	5,557	5,557
Number of shares, Granted	'	'
Number of shares, Exercised	'	'
Number of shares, Cancelled or expired	'	'
Options Outstanding, Ending Balance	5,557	5,557
Weighted average exercise price per share, Outstanding, Beginning Balance	$20.25	$20.25
Weighted average exercise price per share, Granted	'	'
Weighted average exercise price per share, Exercised	'	'
Weighted average exercise price per share, Cancelled or expired	'	'
Weighted average exercise price per share, Outstanding, Ending balance	$20.25	$20.25

ShareBased_Compensation_Detail1

Share-Based Compensation (Details 1) (Stock options [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Stock options [Member]	'	'
Options and warrants expensed	'	'
Risk-free interest rates	0.78%	'
Expected life	'3 years	'
Expected dividends	0.00%	'
Expected volatility	75.00%	'
Vycor Common Stock fair value	$2.05	'

ShareBased_Compensation_Detail2

Share-Based Compensation (Details Textual) (USD $)

1 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

12 Months Ended

2 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

Jul. 31, 2013

14-May-14

Sep. 30, 2014

Feb. 24, 2014

Jan. 02, 2014

Sep. 30, 2013

Sep. 30, 2014

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Dec. 31, 2013

Nov. 30, 2013

Nov. 30, 2013

Jan. 02, 2014

Feb. 29, 2008

Feb. 29, 2008

31-May-10

Feb. 29, 2008

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Jun. 02, 2013

Mar. 31, 2014

Common Stock [Member]

Stock options [Member]

Stock options [Member]

Stock Warrants [Member]

Stock Warrants [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

Dr Donald O Rourke [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Stock Option Plan [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Non Employee Stock Compensation [Member]

Consulting Agreement [Member]

Consulting Agreement [Member]

Extension Agreement [Member]

Extension Agreement [Member]

Advisory Agreement [Member]

Advisory Agreement [Member]

Stock Warrants [Member]

Chief Executive Officer [Member]

President [Member]

President [Member]

Steven Girgenti [Member]

Dr Oscar Bronsther [Member]

Alvaro Pascual - Leone [Member]

Jason Barton [Member]

Jose Romano [Member]

Josef Zihl [Member]

Lowell Rush [Member]

Board of Directors Chairman [Member]

Scientific Advisory Board [Member]

Fountainhead [Member]

Del Mar Consulting [Member]

Alex Partners, LLC [Member]

J and M Group, LLC [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Subsequent Event [Member]

Share-Based Compensation (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Ownership percentage of outstanding voting stock for the options to be granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'More than 10%.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of options granted

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Not less than 110% of the fair market value of the common stock on the grant date.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Option expired period determined by the board of directors

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Not extend mare than 10 years from the grant date.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Outstanding voting stock expire from grant date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period for employees

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares, Granted

'

'

'

'

'

'

'

'

'

5,226,120

'

'

'

'

'

500,000

'

500,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of number of shares covered by plan

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price per share

'

'

'

'

'

'

'

'

'

$2.61

'

'

'

'

'

$0.14

'

$0.14

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on first anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on second anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of options vested on third anniversary

'

'

'

'

'

'

'

'

'

'

'

'

'

'

33.33%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Grant expire date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

12-Feb-18

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Options cancelled or expired

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

166,667

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share based compensation expenses

'

'

'

'

'

'

$43,020

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$78,620

'

'

'

$66,000

'

Weighted-average remaining contractual life of outstanding options

'

'

'

'

'

'

'

'3 years 7 months 17 days

'

'2 years 3 months 29 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based compensation shares issued to nonemployees for services, share

'

'

'

'

'

'

18,000

'

'

'

'

33,000

27,000

'

'

'

'

'

6,532

6,222

2,007

1,944

1,944

4,014

5,718

'

'

'

18,988

3,000

2,000

'

2,500

Share-based compensation shares issued to nonemployees for services, value

'

'

319,050

'

'

'

43,020

'

'

21,510

'

66,000

54,000

'

'

'

'

'

15,000

15,000

4,688

4,688

4,688

9,375

13,750

23,438

43,750

'

45,000

5,400

3,600

'

4,700

consultancy agreement period

'

'

'

'

'

'

'

'

'

'

'

'3 months

'3 months

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total unrecognized compensation costs related to warrant and stock awards and non-vested options

'

'

'

'

'

175,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stock issued during period, Restricted Stock, shares

30,000

45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

30,000

'

Stock Issued during period, Restricted Stock, value

66,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

66,000

'

Warrants issued to purchase common stock shares, Shares

'

'

2,777,808

420,838

792,523

'

'

'

'

'

'

'

'

7,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issued to purchase common stock shares, Value

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,522

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants issue to purchase commmon stock of share at an exercise price

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.08

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Sep. 30, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	$28,820	'
Level 1 [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	'	'
Level 2 [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	'	'
Level 3 [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Warrant Liability	$28,820	'

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2014
			Fair Value, Inputs, Level 3 [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'	'
Balance at December 31, 2013	$28,820	'	'
Issuance of Series A Warrants and Placement Agent Warrants as part of Offering Units on January 2, January 31, February 24, February 28 and March 31, April 25, 2014	'	'	2,103,195
Change in fair value during period	'	'	261,661
Reduction In Liability From Waiver Anti Dilution	'	'	-2,336,036
Balance at September 30, 2014	$28,820	'	$28,820

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (Warrant [Member], USD $)	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Warrant [Member]	'	'
Fair Value Assumptions [Abstract]	'	'
Risk-free interest rates	'	'
Risk-free interest rates, Minimum	0.58%	'
Risk-free interest rates, Maximum	0.93%	'
Expected life	'3 years	'0 years
Expected dividends	0.00%	'
Expected volatility	'	'
Expected volatility, Minimum	71.00%	'
Expected volatility, Maximum	97.00%	'
Vycor Common Stock fair value minimum	$1.88	'
Vycor Common Stock fair value maximum	$2.70	'

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details Textual)	9 Months Ended
	Sep. 30, 2014
Fair Value measurements (Textuals)	'
Issuance Of Series A Warrants And Placement Agent Warrants Shares	2,397,631
Fair Value, Measurements, Recurring [Member]	'
Fair Value measurements (Textuals)	'
Issuance Of Series A Warrants And Placement Agent Warrants Shares	34,723

Commitments_and_Contingencies_

Commitments and Contingencies (Details)	1 Months Ended		9 Months Ended
	Jun. 30, 2012	Jun. 30, 2012	Sep. 30, 2014	Sep. 30, 2013
	USD ($)	EUR (€)	USD ($)	USD ($)
			sqft
Commitments and Contingencies (Textual)	'	'	'	'
Area of leased building (sq. ft)	'	'	10,000	'
Rent expenses plus sales tax (per month)	'	'	$14,630	'
Term of lease	'	'	'5 years 6 months	'
Lease expiration date	'	'	31-Jul-17	'
Approximate preliminary assessed trade tax	94,000	75,000	'	'
Rent expense	'	'	$150,300	$146,014

Consulting_and_Other_Agreement1

Consulting and Other Agreements (Details) (USD $)	1 Months Ended	3 Months Ended	0 Months Ended	1 Months Ended				0 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended
	Jul. 31, 2013	14-May-14	Jan. 02, 2014	Nov. 30, 2013	Nov. 30, 2012	Nov. 30, 2013	Nov. 30, 2012	Jun. 30, 2014	Mar. 31, 2014	Nov. 30, 2014	Oct. 31, 2014
			Fountainhead [Member]	Del Mar Consulting [Member]	Del Mar Consulting [Member]	Alex Partners, LLC [Member]	Alex Partners, LLC [Member]	Hayden IR, LLC	Hayden IR, LLC	Hayden IR, LLC	Hayden IR, LLC
										Subsequent Event [Member]	Subsequent Event [Member]
Consulting and Other Agreements (Textual)	'	'	'	'	'	'	'	'	'	'	'
Consulting agreement duration	'	'	'	'	'12 months	'	'12 months	'	'12 months	'	'
Shares received under consulting agreement, value	'	'	'	$33,000	'	$27,000	'	'	$8,500	'	'
Cash payment pursuant to consulting agreement	'	'	'	66,000	'	54,000	'	'	'	'	'
Maximum cash payment for consulting services (monthly)	'	'	10,000	'	'	'	'	'	'	'	'
Minimum cash payment for consulting services	'	'	$5,000	'	'	'	'	'	'	'	'
Stock issued during period, Restricted Stock, shares	30,000	45,000	'	'	'	'	'	18,000	36,000	9,000	3,000
Description of agreement	'(i) 90 days from the date of execution of the Agreement or (ii) the end of the offering period of any securities financing undertaken by the Company in connection with the Placement Agent Agreement.	'	'	'	'	'	'	'	'	'	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Jan. 02, 2014

Sep. 30, 2014

Jan. 02, 2014

Jan. 02, 2014

Aug. 31, 2013

Aug. 05, 2014

Sep. 30, 2014

Aug. 05, 2014

Aug. 05, 2014

Sep. 30, 2014

Oct. 31, 2014

Oct. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Oct. 31, 2014

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Consulting Agreement [Member]

Consulting Agreement [Member]

Employment Agreements [Member]

Conversion Agreement [Member]

Subsequent Event [Member]

Fountainhead [Member]

Fountainhead [Member]

Fountainhead [Member]

Fountainhead [Member]

Fountainhead [Member]

Fountainhead [Member]

Fountainhead [Member]

Peter Zachariou [Member]

Peter Zachariou [Member]

Peter Zachariou [Member]

David Cantor [Member]

David Cantor [Member]

Fountainhead and Peter Zachariou [Member]

Maximum [Member]

Minimum [Member]

Consulting Agreement [Member]

Subsequent Event [Member]

Secured Loan One [Member]

Consulting Agreement [Member]

Subsequent Event [Member]

Consulting Agreement [Member]

Subsequent Event [Member]

Related Party Transactions (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loan amount

'

$2,373,556

'

'

'

'

$10,000

'

'

'

'

'

'

$35,000

'

'

$12,642

'

'

$2,247,037

Extension of maturity date

'

'

'Fountainhead amended their Consulting Agreement to extend the term of the Consulting Agreement to to January 2, 2015.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock held

'

'

'

'

'

'

'

'

4.5

'

'

'

'

'

'

'

'

'

'

'

Loan repayment term

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'Fountainhead and Peter Zachariou agreed to extend the maturity of all of the Company's debt obligations due to them due to as of August 9, 2013 (aggregating $2,247,037) to January 2, 2017, subject to the earlier repayment of such debt upon the occurrence of certain specified conditions

Repayment of debt

'

'

'

'

'

'

'

'

91,519

'

'

202,683

34,269

'

20,000

247

12,642

15,000

69,198

'

Annual compensation of employment agreements

'

'

'

'

110,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Description of employment agreements

'

'

'

'

'The aforementioned Employment Agreements provide for annual compensation of $110,000, payment of which is deferred for 12 months from the Effective Date and is subject to the achievement of certain enumerated milestone conditions.

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Decrease in retainer payable to Fountainhead

'

'

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Retainer payable to Fountainhead

'

'

5,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Accrued consulting fee

'

'

'

'

'

1,426,542

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued to Fountainhead

1,085

675

'

45,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common Stock issued to Fountainhead, Shares

10,851,263

6,757,225

'

18,988

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt converted into preferred shares

'

'

'

'

'

'

'

2,355,587

'

'

'

'

'

'

'

'

'

'

'

'

Face amount of the exchanged debt

'

'

'

'

'

'

'

$2,355,587

'

'

'

'

'

'

'

'

'

'

'

'

Common stock price per share

'

'

'

'

'

'

'

$2.15

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, dividend rate, percentage

'

'

'

'

'

'

'

'

'

7.00%

12.00%

'

'

'

'

'

'

'

'

'

Number of additional warrants of common shares

'

'

'

'

'

'

'

50.00%

'

'

'

'

'

'

'

'

'

'

'

'

Exercise price of warrant

'

'

'

'

'

'

'

$3.08

'

'

'

'

'

'

'

'

'

'

'

'

Period of warrants

'

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

Number of shares of common stock percentage

'

'

'

'

'

'

'

75.00%

'

'

'

'

'

'

'

'

'

'

'

'

Warrants expiration description

'

'

'

'

'

'

'

'

'Warrants expiring in 2015

'

'

'

'

'

'

'

'

'

'

'

Subsequent_Events_Details

Subsequent Events (Details) (USD $)

Sep. 30, 2014

Dec. 31, 2013

Sep. 30, 2014

Sep. 30, 2014

Sep. 30, 2014

Aug. 31, 2013

Oct. 31, 2014

Aug. 31, 2014

Aug. 31, 2014

Aug. 31, 2014

Nov. 30, 2014

Oct. 31, 2014

Jun. 30, 2015

Mar. 31, 2015

Dec. 31, 2014

Series B Warrants [Member]

JLS [Member]

JDR [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Common Stock [Member]

Peter Zachariou [Member]

Steven Girgenti [Member]

Alvaro Pasual Leone [Member]

Josef Zihl [Member]

Fountainhead Capital Partners Limited [Member]

Fountainhead Capital Partners Limited [Member]

JLS [Member]

JLS [Member]

JLS [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Common Stock [Member]

Subsequent Events (Textual)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Common stock issued in consideration for services

'

'

'

$100,000

'

'

'

$5,000

$1,427

$3,125

$19,800

'

'

'

'

Common stock issued in consideration for services, Shares

'

'

'

196,000

'

'

'

1,984

713

1,563

9

'

'

'

'

Common stock shares issued

'

'

1,130,621

'

'

'

'

'

'

'

'

'

100,000

100,000

100,000

Paid to related party agreement

'

'

'

'

15,000

'

'

'

'

'

'

'

'

'

'

Additional payments to related party

'

'

'

'

15,000

'

'

'

'

'

'

'

'

'

'

Loan amount

'

$2,373,556

'

'

'

$10,000

$12,642

'

'

'

'

$34,269

'

'

'